EUVIMEDEUVIMED entdecken
Crossref

Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated degradation

Dongchao Xu, Yuanling Zhu, Wuhan Ye, Yuhua Yu, Xuehui Wang, Chenshan Xu, Ke Jiang, Wangyang Chen, Xiaofeng Zhang, Hongzhang Shen

Phytomedicine · 2025-11 · 148 · 157245

DOI: 10.1016/j.phymed.2025.157245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2025-11. Verfasst von Dongchao Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou 310006, China; Hangzhou…. Hauptthemen laut MEDLINE: PPAR alpha, Pancreatic Neoplasms, Benzylisoquinolines, Antineoplastic Agents, Phytogenic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Zhejiang Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pancreatic cancer (PC) is well known for its high lethality, and limited therapeutic options are currently available. Daurisoline (DAU), a bisbenzylisoquinoline alkaloid isolated from Menispermum dauricum DC., has demonstrated antitumor effects in several cancers, although its precise mechanism of action remains unclear. PURPOSE: This study evaluated the DAU-mediated inhibition of pancreatic cancer and the mechanisms responsible. METHODS: DAU's inhibitory effects on PC cells were measured through EdU, CCK-8, wound healing, Transwell, and flow cytometry assays. Bioinformatics analysis revealed molecular expression alterations between PC cells treated with or without DAU. The roles of the PPARα and JAK2/STAT3 pathway in DAU-mediated PC suppression were investigated via PPARα lentiviral transduction and STAT3 activator treatment, respectively. Coimmunoprecipitation assays were performed to confirm the impact of DAU on PPARα ubiquitination and identify the specific ubiquitin ligase involved. RESULTS: Our findings revealed that DAU suppresses the proliferation of pancreatic cancer cells in a time- and dose-dependent manner while also inhibiting cell migration and invasion. Additionally, DAU arrests the cell cycle at the G1 phase and induces apoptosis. Mechanistically, bioinformatics analysis combined with experimental validation demonstrated that DAU binds to PPARα, increases its expression, and subsequently suppresses JAK2/STAT3 signaling. Notably, DAU competitively blocks the Trim63-PPARα interaction by binding to PPARα, thereby suppressing PPARα ubiquitination to increase its protein stability. CONCLUSION: DAU inhibits the JAK2/STAT3 signaling pathway by preventing PPARα ubiquitination, thereby suppressing the progression of PC cells. This research provides a new therapeutic strategy and a promising compound for treatment of PC through suppression of the ubiquitination pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PPAR alphaPancreatic NeoplasmsBenzylisoquinolinesAntineoplastic Agents, PhytogenicHumansCell Line, TumorSTAT3 Transcription FactorUbiquitinationCell ProliferationCell MovementJanus Kinase 2Signal TransductionApoptosis

Stichwörter der Autor:innen

DaurisolineJAK2/STAT3 signaling pathwayPPARαPancreatic ductal adenocarcinomaUbiquitination

Substanzen

PPAR alphaSTAT3 Transcription FactorBenzylisoquinolinesSTAT3 protein, humanJAK2 protein, humanJanus Kinase 2Antineoplastic Agents, PhytogenicPPARA protein, human

Autor:innen und Institutionen

  • Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou 310006, China; Hangzhou Institute of Digestive Diseases, Hangzhou 310000, China; Key Laborato…
  • Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou 310006, China.

Förderung

  • Zhejiang Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Xu, D., Zhu, Y., Ye, W., Yu, Y., Wang, X., Xu, C., Jiang, K., Chen, W., Zhang, X., & Shen, H. (2025). Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated degradation. Phytomedicine, 148, 157245. https://doi.org/10.1016/j.phymed.2025.157245

Vancouver

Xu D, Zhu Y, Ye W, Yu Y, Wang X, Xu C, et al. Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated degradation. Phytomedicine. 2025;148:157245. doi:10.1016/j.phymed.2025.157245

BibTeX
@article{Xu2025,
  author = {Xu, Dongchao and Zhu, Yuanling and Ye, Wuhan and Yu, Yuhua and Wang, Xuehui and Xu, Chenshan and Jiang, Ke and Chen, Wangyang and Zhang, Xiaofeng and Shen, Hongzhang},
  title = {Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated degradation},
  journal = {Phytomedicine},
  year = {2025},
  volume = {148},
  pages = {157245},
  doi = {10.1016/j.phymed.2025.157245}
}
Kostenlos starten →